A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment With DIO-902 [DiObex] or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-502)
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Atorvastatin; DIO 902
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors DiObex
- 31 Aug 2018 Biomarkers information updated
- 12 Nov 2008 Status changed from recruiting to discontinued, as reported in ClinicalTrials.gov record.
- 05 Apr 2007 New trial record.